NCT05423977 - Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

May 5, 2023

Study Completion Date

July 7, 2026

Conditions

HER2-positive Advanced Solid Tumor

Interventions

DRUG

ZV0203

Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.

Trial Locations (1)

Unknown

PKUCare Luzhong Hospital, Zigong